- Home
- USEA vs ICU Comparison
USEA vs ICU Comparison
Compare USEA & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEA
- ICU
- Stock Information
- Founded
- USEA 2004
- ICU 2018
- Country
- USEA Greece
- ICU United States
- Employees
- USEA N/A
- ICU N/A
- Industry
- USEA Marine Transportation
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- USEA Consumer Discretionary
- ICU Health Care
- Exchange
- USEA Nasdaq
- ICU Nasdaq
- Market Cap
- USEA 10.5M
- ICU 10.4M
- IPO Year
- USEA N/A
- ICU N/A
- Fundamental
- Price
- USEA $1.28
- ICU $1.18
- Analyst Decision
- USEA Strong Buy
- ICU
- Analyst Count
- USEA 1
- ICU 0
- Target Price
- USEA $6.00
- ICU N/A
- AVG Volume (30 Days)
- USEA 23.3K
- ICU 144.0K
- Earning Date
- USEA 05-22-2025
- ICU 05-14-2025
- Dividend Yield
- USEA 3.13%
- ICU N/A
- EPS Growth
- USEA N/A
- ICU N/A
- EPS
- USEA N/A
- ICU N/A
- Revenue
- USEA $42,595,000.00
- ICU $428,000.00
- Revenue This Year
- USEA N/A
- ICU $648.15
- Revenue Next Year
- USEA $11.02
- ICU $100.00
- P/E Ratio
- USEA N/A
- ICU N/A
- Revenue Growth
- USEA N/A
- ICU N/A
- 52 Week Low
- USEA $1.00
- ICU $1.11
- 52 Week High
- USEA $2.84
- ICU $13.85
- Technical
- Relative Strength Index (RSI)
- USEA 50.08
- ICU 35.77
- Support Level
- USEA $1.22
- ICU $1.13
- Resistance Level
- USEA $1.31
- ICU $1.34
- Average True Range (ATR)
- USEA 0.07
- ICU 0.07
- MACD
- USEA 0.00
- ICU 0.00
- Stochastic Oscillator
- USEA 40.84
- ICU 23.81
About USEA United Maritime Corporation
United Maritime Corp operates as a shipping company currently specializing in the seaborne transportation of dry bulk commodities. It currently operates one LR2 tanker vessel and three Capesize dry bulk vessels, two Kamsarmax dry bulk vessels, and three Panamax dry bulk vessels, with an aggregate cargo-carrying capacity of approximately 1,004,289 dwt.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.